Reuters 
(6/9) reported that Amgen Inc. has announced that its Sensipar
(cinacalcet) medication did not meet the goal of a late-stage study.
(6/9) reported that Amgen Inc. has announced that its Sensipar
(cinacalcet) medication did not meet the goal of a late-stage study.
Dow Jones Newswire
(6/9) reported, "Amgen said Friday it undertook the Phase 3 trial of
Sensipar to discover whether the drug could positively impact the high
rates of mortality and incidences like heart failure experienced by
patients with chronic kidney disease that are receiving dialysis." The
findings, "however, were not statistically significant, Amgen said."
(6/9) reported, "Amgen said Friday it undertook the Phase 3 trial of
Sensipar to discover whether the drug could positively impact the high
rates of mortality and incidences like heart failure experienced by
patients with chronic kidney disease that are receiving dialysis." The
findings, "however, were not statistically significant, Amgen said."
No comments:
Post a Comment